sangamo
bioscienc
wwwsangamocom
said
acquir
ceregen
develop
adenoassoci
viral
aav
gene
therapi
deal
expand
sangamo
capabl
aav
manufactur
price
disclos
sangamo
acquir
ceregen
preclin
clinic
therapeut
programsinclud
ongo
phase
trial
evalu
product
aav
vector
carri
gene
nerv
growth
factor
ngf
patient
alzheim
diseas
march
ceregen
obtain
roch
genentech
subsidiari
licens
exclus
worldwid
right
ngf
anoth
gene
neurotroph
factor
financi
term
disclos
design
address
loss
cholinerg
neuron
associ
memori
loss
cognit
declin
alzheim
use
aav
produc
steadi
suppli
ngf
brain
doubleblind
placebocontrol
phase
trial
followup
stage
evalu
effect
treatment
establish
clinic
end
point
cognit
function
qualiti
life
result
expect
releas
ceregen
collabor
alzheim
diseas
cooper
studi
adc
base
univers
california
san
diego
ucsd
million
grant
nih
nation
institut
age
support
trial
patient
mild
moder
alzheim
acquisit
sangamo
receiv
issu
pend
inlicens
patent
includ
patent
famili
cover
aav
vector
platform
manufactur
method
well
therapeut
transgen
ceregenedevelop
needl
devic
direct
administr
aav
brain
sangamo
said
deal
also
give
access
among
thing
gmp
master
cell
bank
well
databas
preclin
efficaci
toxicolog
studi
document
support
ceregen
investig
new
drug
ind
applic
sangamo
said
document
help
prepar
file
ind
applic
engin
class
dnabind
protein
compani
call
zinc
finger
dnabind
protein
zfp
therapeut
especi
target
brain
engin
zfp
recogn
specif
dna
sequenc
sangamo
enabl
creation
sequencespecif
zfp
nucleas
zfn
gene
modif
zfp
transcript
factor
capabl
control
gene
express
thu
cell
function
sangamo
lead
pipelin
product
use
zfnbase
approach
modifi
gene
encod
major
coreceptor
use
hiv
infect
immun
cell
compani
first
applic
technolog
autolog
cell
product
subject
ongo
phase
trial
two
phase
two
phase
studi
patient
hiv
aid
compani
also
preclin
program
develop
hematopoiet
stem
cell
product
researchstag
program
develop
vivo
product
sangamo
said
subsidiari
would
merg
ceregen
would
continu
wholli
own
subsidiari
compani
acquisit
expect
close
septemb
subject
customari
condit
includ
approv
sangamo
sharehold
regulatori
file
us
secur
exchang
commiss
sangamo
said
requir
pay
ceregen
stockhold
doubledigit
percentag
upfront
mileston
payment
receiv
grant
thirdparti
licens
develop
commerci
alzheim
anoth
ceregen
drug
candid
parkinson
diseas
huntington
diseas
sangamo
commerci
either
product
requir
pay
ceregen
stockhold
royaltylik
earnout
payment
percentag
net
sale
rang
low
doubl
digit
depend
amount
net
sale
subject
reduct
sangamo
accord
file
acquisit
termin
either
compani
close
novemb
sooner
mutual
consent
file
ad
genvec
wwwgenveccom
said
withdrawn
plan
liquid
dissolv
compani
approv
board
may
favor
new
strategi
seek
maxim
valu
technolog
assetsinclud
hear
loss
collabor
novarti
genvec
new
strategi
led
chang
top
presid
ceo
cynthia
collin
left
compani
resign
board
director
succeed
collin
execut
board
role
dougla
j
swirski
genvec
svp
cfo
sinc
genvec
decis
withdraw
plan
dissolut
result
increas
confid
mileston
collabor
realiz
abil
bring
expenditur
line
resourc
swirski
said
statement
includ
potenti
mileston
payment
novarti
cash
cash
equival
invest
fund
oper
least
end
withdraw
dissolut
plan
approv
may
month
report
yearoveryear
drop
annual
revenu
last
year
genvec
also
take
time
necessari
find
license
collabor
assign
reason
valu
technolog
rather
valu
technolog
shadow
dissolut
swirski
ad
human
gene
therapi
octob
mari
ann
liebert
inc
doi
doi
doi
board
five
member
depart
board
collin
edward
connor
jr
md
adel
af
mahmoud
md
phd
kevin
rooney
follow
unanim
approv
director
withdraw
dissolut
plan
approv
may
approv
new
oper
strategi
genvec
struggl
develop
success
gene
therapi
treatment
despit
win
condit
approv
june
vaccin
intend
treat
footandmouth
diseas
cattl
two
month
later
septemb
genvec
cut
workforc
posit
save
cash
say
reduct
would
allow
fund
oper
third
quarter
even
without
mileston
payment
may
receiv
ongo
collabor
novarti
time
genvec
report
million
cash
cash
equival
shortterm
invest
end
second
quarter
genvec
end
revenu
loss
million
slide
compani
blame
yearoveryear
declin
million
hear
loss
balanc
disord
program
million
hiv
program
million
footandmouth
diseas
program
audent
therapeut
wwwaudentestxcom
close
million
seri
financ
led
orbim
advisor
particip
ventur
versant
ventur
startup
biotech
develop
commerci
new
treatment
rare
muscl
diseas
use
aav
gene
therapi
technolog
audent
said
use
fund
advanc
two
aavbas
lead
xlink
myotubular
myopathi
xlmtm
pomp
diseasea
well
evalu
addit
candid
program
compani
headquart
san
francisco
california
financ
tremend
step
forward
develop
new
potenti
treatment
patient
affect
seriou
orphan
muscl
diseas
matthew
r
patterson
audent
presid
ceo
said
statement
patterson
join
thoma
j
schuetz
md
phd
orbim
advisor
found
audent
novemb
dr
schuetz
act
independ
director
audent
board
chair
jonathan
silverstein
jd
gener
partner
cohead
global
privat
equiti
orbim
advisor
includ
kush
parmar
md
phd
princip
ventur
thoma
woiwod
phd
ventur
partner
versant
ventur
patterson
twelv
day
announc
seri
financ
audent
grant
exclus
worldwid
licens
regenx
bioscienc
develop
commerci
product
treat
xlmtm
pomp
diseas
use
regenx
nav
vector
return
audent
agre
pay
regenx
upfront
payment
mileston
fee
undisclos
royalti
net
sale
product
incorpor
nav
regenx
hold
exclus
right
portfolio
patent
patent
applic
pertain
nav
technolog
relat
applic
compani
plan
initi
develop
treatment
rare
genet
diseas
includ
hypercholesterolemia
mucopolysaccharidos
retin
pigmentosa
ensur
continu
access
nav
technolog
partnership
licens
global
collabor
least
mammalian
virus
within
nine
viral
famili
await
discoveri
investig
accord
team
research
unit
state
bangladesh
mexico
appli
new
framework
discoveri
novel
virus
wildlif
produc
firstev
estim
number
virus
exist
mammalian
host
collect
evid
virus
could
provid
inform
critic
earli
detect
mitig
diseas
outbreak
human
team
conclud
studi
strategi
estim
unknown
viral
divers
mammal
publish
septemb
journal
mbio
publish
associ
american
academi
microbiolog
anthoni
et
al
estim
cost
discov
virus
billion
billion
total
divers
annual
studi
time
frame
would
repres
small
fraction
cost
mani
pandem
zoonos
team
observ
studi
econom
impact
sever
acut
respiratori
syndrom
sar
pandem
alon
calcul
billion
say
undertak
would
prevent
anoth
outbreak
like
sar
nonetheless
learn
explor
global
viral
divers
could
mitig
outbreak
facilit
better
surveil
rapid
diagnost
test
said
simon
anthoni
dphil
scientist
center
infect
immun
cii
columbia
univers
mailman
school
public
health
investig
cii
ecohealth
alliancean
intern
organ
scientist
dedic
conserv
biodiversitycollect
biolog
sampl
indian
fli
fox
pteropu
giganteu
largest
fli
mammal
mammalian
wildlif
host
identifi
sourc
sever
outbreak
nipah
viru
return
laboratori
team
use
polymeras
chain
reaction
identifi
virus
nine
viral
famili
five
previous
known
includ
two
human
bocavirus
avian
adenoviru
humanbovin
betacoronaviru
avian
gammacoronaviru
newli
discov
includ
famili
nipah
viru
research
estim
anoth
three
rare
virus
unaccount
sampl
up
estim
virus
fli
fox
number
extrapol
known
mammal
produc
estim
total
least
virus
estim
could
much
higher
team
said
base
use
highthroughput
sequenc
method
develop
cii
expect
find
addit
viral
famili
among
question
like
affect
viral
count
depend
answer
repres
fli
fox
sampl
fli
fox
bangladesh
mammal
speci
harbor
similar
number
virus
extent
virus
share
speci
speci
also
cost
fli
fox
expedit
bangladesh
rel
low
compar
similar
undertak
anim
live
remot
areasa
factor
team
said
could
rais
cost
collect
sampl
dr
anthoni
one
two
correspond
author
studi
peter
daszak
phd
presid
ecohealth
allianc
two
paper
publish
day
journal
scienc
illustr
potenti
treat
debilit
inherit
condit
lentivir
vector
gene
transfer
hematopoiet
stemprogenitor
cell
hspc
hematopoiet
stem
cell
hsc
first
paper
lentivir
hematopoiet
stem
cell
gene
therapi
patient
wiskottaldrich
syndrom
aiuti
et
al
chronicl
use
research
franc
germani
itali
turkey
unit
kingdom
unit
state
lentivir
vector
encod
function
version
gene
encod
wasp
cytoskeletonregul
protein
implic
inherit
immunodefici
wiskottaldrich
syndrom
luigi
naldini
md
phd
scientif
director
san
raffael
scientif
institut
milan
itali
team
appli
vector
genet
correct
hspc
three
patient
reinfus
three
patient
show
stabl
engraft
waspexpress
cell
improv
platelet
count
immun
function
clinic
score
dr
naldini
colleagu
report
ad
accord
vector
integr
analys
genecorrect
hspc
result
highli
polyclon
multilineag
hematopoiesi
research
note
lentivir
gene
therapi
induc
select
integr
near
oncogen
observ
aberr
clonal
expans
month
month
posttherapi
although
extend
clinic
observ
requir
establish
longterm
safeti
lentivir
gene
therapi
repres
promis
treatment
research
conclud
lentivir
hematopoiet
stem
cell
gene
therapi
benefit
metachromat
leukodystrophi
biffi
et
al
dr
naldini
team
research
germani
itali
lebanon
netherland
unit
kingdom
unit
state
took
similar
approach
transfer
function
arylsulfatas
arsa
gene
hsc
three
presymptomat
patient
show
genet
biochem
neurophysiolog
evid
late
infantil
metachromat
leukodystrophi
mld
inherit
lysosom
storag
diseas
